New Cancer Vaccine Reprogrammes Tumours for Immune System Attack
A revolutionary vaccine injected directly into tumours could significantly improve survival rates for patients with hard-to-treat cancers. The one-off injection works by chemically reprogramming cancer cells, making them fully visible to the body's immune defences. This triggers the release of disease-fighting T-cells that target and destroy the malignant growth.
Remarkable Laboratory Results
In experimental trials with mice suffering from bowel cancer, the vaccine demonstrated 100% effectiveness at completely eradicating tumours. Separate laboratory tests on human breast cancer cells produced similarly promising outcomes, with the treatment resulting in complete cellular destruction. These findings suggest a potential breakthrough in cancer therapy approaches.
Evolution of Cancer Treatment
For decades, cancer management has relied primarily on established techniques like chemotherapy and radiotherapy. Chemotherapy employs powerful drugs to prevent malignant cells from reproducing, while radiotherapy uses high-energy radiation to destroy tumour DNA and halt spread. Although chemotherapy can be effective, it often works less efficiently against metastatic cancer and causes significant side effects including nausea, hair loss, and heart palpitations by targeting both healthy and cancerous cells.
Radiotherapy alone eradicates approximately 40% of cancers but also brings adverse effects like skin irritation around treatment areas. The past ten to fifteen years have witnessed transformative developments with immunotherapy drugs such as pembrolizumab and nivolumab. These medications work by removing inhibitory signals from the immune system, enabling it to identify and attack cancerous cells more effectively.
Immunotherapy's Impact and Limitations
Immunotherapy has dramatically improved outcomes for certain cancers, particularly malignant melanoma. Studies indicate the five-year survival rate for melanoma patients receiving these drugs has increased by around 50% since their introduction. Many patients now survive a decade or more after diagnosis, compared to an average survival time of just six months during the 1990s.
However, immunotherapy drugs demonstrate variable effectiveness across patients. Research shows only about 40% of individuals fully respond to treatment. In other cases, tumours may temporarily shrink before resuming growth weeks or months later. This variability is thought to occur because T-cells can become over-stimulated by tumour presence, weakening their attacking capabilities.
How the New Vaccine Works
The innovative vaccine, called iVAC (intratumoural vaccination chimera), combines two mechanisms to enhance cancer-fighting potential. Like standard immunotherapy, it blocks the PD-L1 protein that cancer cells use to hide from immune detection. Simultaneously, it chemically reprograms tumour cells to proactively attract killer T-cells by making them produce antigens typically found on foreign invaders like viruses or bacteria.
Although cancer cells naturally produce some antigens, these signals are often weak, allowing tumours to escape full immune system assault. Developed by scientists at Peking University in China, the new vaccine amplifies this antigen response, enabling the body's defences to react more aggressively against cancerous growths.
Expert Perspectives and Future Directions
Tim Elliott, Professor of Immuno-Oncology at the University of Oxford, finds this dual-mechanism approach particularly promising. "It combines two mechanisms in one drug and is generating a lot of excitement," he notes. "A similar approach is already being investigated in trials, but with drugs given intravenously rather than injected directly into tumours."
However, experts acknowledge potential limitations. Professor Elliott highlights practical challenges: "Injecting the tumour is fine if there's a single large mass. But what about when the cancer is highly disseminated in lots of tiny tumours, or when it's small, inaccessible and hard to locate?"
Karl Peggs, Professor of Cancer Immunotherapy at University College London Hospitals NHS Foundation Trust, echoes these concerns while acknowledging the scientific elegance of the approach. "It's a scientifically elegant way of delivering the two elements of treatment – nice and neat for mice experiments, but quite challenging to deliver clinically," he observes.
The research team plans to begin patient trials within the next few years, focusing initially on the most difficult-to-treat tumours. Specific cancer types for initial testing and potential side effects remain to be determined as research progresses toward clinical application.
